Agricultural exposures to carbamate herbicides and fungicides and central nervous system tumour incidence in the cohort AGRICAN.


Journal

Environment international
ISSN: 1873-6750
Titre abrégé: Environ Int
Pays: Netherlands
ID NLM: 7807270

Informations de publication

Date de publication:
09 2019
Historique:
received: 20 12 2018
revised: 27 05 2019
accepted: 27 05 2019
pubmed: 26 7 2019
medline: 5 3 2020
entrez: 26 7 2019
Statut: ppublish

Résumé

Pesticides exposures could be implicated in the excess of Central Nervous System (CNS) tumors observed in farmers, but evidence concerning individual pesticides remains limited. Carbamate derivative pesticides, including herbicides and fungicides (i.e. (thio/dithio)-carbamates), have shown evidence of carcinogenicity in experimental studies in animals. In the French AGRICAN cohort, we assessed the associations between potential exposures to carbamate herbicides and fungicides and the incidence of CNS tumors, overall and by histological subtype. AGRICAN enrolled 181,842 participants involved in agriculture. Incident CNS tumors were identified by linkage with cancer registries from enrollment (2005-2007) until 2013. Individual exposures were assessed by combining information on lifetime periods of pesticide use on crops and the French crop-exposure matrix PESTIMAT, for each of the 14 carbamate and thiocarbamate herbicides and the 16 carbamate and dithiocarbamate fungicides registered in France since 1950. Associations were estimated using proportional hazard models with age as the underlying timescale, adjusting for gender, educational level and smoking. During an average follow-up of 6.9 years, 381 incident cases of CNS tumors occurred, including 164 gliomas and 134 meningiomas. Analyses showed increased risks of CNS tumors with overall exposure to carbamate fungicides (Hazard Ratio, HR = 1.88; 95% CI: 1.27-2.79) and, to a lesser extent, to carbamate herbicides (HR = 1.44; 95% CI: 0.94-2.22). Positive associations were observed with specific carbamates, including some fungicides (mancozeb, maneb, metiram) and herbicides (chlorpropham, propham, diallate) already suspected of being carcinogens in humans. Although some associations need to be corroborate in further studies and should be interpreted cautiously, these findings provide additional carcinogenicity evidence for several carbamate fungicides and herbicides.

Sections du résumé

BACKGROUND
Pesticides exposures could be implicated in the excess of Central Nervous System (CNS) tumors observed in farmers, but evidence concerning individual pesticides remains limited. Carbamate derivative pesticides, including herbicides and fungicides (i.e. (thio/dithio)-carbamates), have shown evidence of carcinogenicity in experimental studies in animals. In the French AGRICAN cohort, we assessed the associations between potential exposures to carbamate herbicides and fungicides and the incidence of CNS tumors, overall and by histological subtype.
METHODS
AGRICAN enrolled 181,842 participants involved in agriculture. Incident CNS tumors were identified by linkage with cancer registries from enrollment (2005-2007) until 2013. Individual exposures were assessed by combining information on lifetime periods of pesticide use on crops and the French crop-exposure matrix PESTIMAT, for each of the 14 carbamate and thiocarbamate herbicides and the 16 carbamate and dithiocarbamate fungicides registered in France since 1950. Associations were estimated using proportional hazard models with age as the underlying timescale, adjusting for gender, educational level and smoking.
RESULTS
During an average follow-up of 6.9 years, 381 incident cases of CNS tumors occurred, including 164 gliomas and 134 meningiomas. Analyses showed increased risks of CNS tumors with overall exposure to carbamate fungicides (Hazard Ratio, HR = 1.88; 95% CI: 1.27-2.79) and, to a lesser extent, to carbamate herbicides (HR = 1.44; 95% CI: 0.94-2.22). Positive associations were observed with specific carbamates, including some fungicides (mancozeb, maneb, metiram) and herbicides (chlorpropham, propham, diallate) already suspected of being carcinogens in humans.
CONCLUSIONS
Although some associations need to be corroborate in further studies and should be interpreted cautiously, these findings provide additional carcinogenicity evidence for several carbamate fungicides and herbicides.

Identifiants

pubmed: 31344646
pii: S0160-4120(18)33169-6
doi: 10.1016/j.envint.2019.05.070
pii:
doi:

Substances chimiques

Carbamates 0
Carcinogens 0
Fungicides, Industrial 0
Herbicides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104876

Investigateurs

P Arveux (P)
S Bara (S)
A M Bouvier (AM)
T Busquet (T)
M Colonna (M)
G Coureau (G)
M Delanoé (M)
P Grosclaude (P)
A V Guizard (AV)
P Herbrecht (P)
J J Laplante (JJ)
B Lapotre-Ledoux (B)
G Launoy (G)
D Lenoir (D)
E Marrer (E)
E Marcotullio (E)
M Maynadié (M)
F Molinié (F)
A Monnereau (A)
A Paumier (A)
P Pouzet (P)
J M Thibaudier (JM)
X Troussard (X)
M Velten (M)
E Wavelet (E)
A S Woronoff (AS)

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Clément Piel (C)

EPICENE team, ISPED, U1219 INSERM, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France.

Camille Pouchieu (C)

EPICENE team, ISPED, U1219 INSERM, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France; Registre des tumeurs primitives du système nerveux central de la Gironde, ISPED, Centre INSERM U1219, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France.

Camille Carles (C)

EPICENE team, ISPED, U1219 INSERM, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France; CHU de Bordeaux, Service de Médecine du Travail et Pathologies Professionnelles, Bordeaux, France.

Béatrix Béziat (B)

EPICENE team, ISPED, U1219 INSERM, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France.

Mathilde Boulanger (M)

INSERM, U1086 Anticipe Axe Cancers et Préventions, Caen, France; Université de Caen Normandie, Caen, France; Centre de Lutte Contre le Cancer François Baclesse, Caen, France.

Mathilde Bureau (M)

EPICENE team, ISPED, U1219 INSERM, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France.

Amandine Busson (A)

INSERM, U1086 Anticipe Axe Cancers et Préventions, Caen, France; Université de Caen Normandie, Caen, France; Centre de Lutte Contre le Cancer François Baclesse, Caen, France.

Anne Grüber (A)

EPICENE team, ISPED, U1219 INSERM, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France; Registre des tumeurs primitives du système nerveux central de la Gironde, ISPED, Centre INSERM U1219, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France.

Yannick Lecluse (Y)

INSERM, U1086 Anticipe Axe Cancers et Préventions, Caen, France; Université de Caen Normandie, Caen, France; Centre de Lutte Contre le Cancer François Baclesse, Caen, France.

Lucile Migault (L)

EPICENE team, ISPED, U1219 INSERM, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France.

Marine Renier (M)

INSERM, U1086 Anticipe Axe Cancers et Préventions, Caen, France; Université de Caen Normandie, Caen, France; Centre de Lutte Contre le Cancer François Baclesse, Caen, France.

Virginie Rondeau (V)

EPICENE team, ISPED, U1219 INSERM, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France.

Xavier Schwall (X)

EPICENE team, ISPED, U1219 INSERM, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France.

Séverine Tual (S)

INSERM, U1086 Anticipe Axe Cancers et Préventions, Caen, France; Université de Caen Normandie, Caen, France; Centre de Lutte Contre le Cancer François Baclesse, Caen, France.

Lebailly Pierre (L)

INSERM, U1086 Anticipe Axe Cancers et Préventions, Caen, France; Université de Caen Normandie, Caen, France; Centre de Lutte Contre le Cancer François Baclesse, Caen, France.

Isabelle Baldi (I)

EPICENE team, ISPED, U1219 INSERM, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France; Registre des tumeurs primitives du système nerveux central de la Gironde, ISPED, Centre INSERM U1219, Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France; CHU de Bordeaux, Service de Médecine du Travail et Pathologies Professionnelles, Bordeaux, France. Electronic address: isabelle.baldi@u-bordeaux.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH